Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents. RESEARCH DESIGN AND METHODS: After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m2) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose <100 mg/dL (<5.6 mmol/L) up to a maximum dose of 60 units/day. The primary outcome was change in HbA1c levels at 30 weeks. RESULTS: HbA1c decreased from 8.5% (69 mmol/mol) to 8.1% (65 mmol/mol) during the run-in period. After randomization, iGlarLixi showed greater reductions in HbA1c from baseline compared with iGlar (–1.1% vs. –0.6%, P < 0.0001), reaching a mean final HbA1c of 6.9% (52 mmol/mol) compared with 7.5% (58 mmol/mol) for iGlar. HbA1c <7.0% (53 mmol/mol) was achieved in 55% of iGlarLixi patients compared with 30% on iGlar. Mean body weight decreased by 0.7 kg with iGlarLixi and increased by 0.7 kg with iGlar (1.4 kg difference, P < 0.0001). Documented symptomatic hypoglycemia (≤70 mg/dL) was comparable between groups. Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi. CONCLUSIONS: Compared with iGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xedratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant improvements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216 -220).”
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“mitigate the weight gain observed with insulin therapy (4,6–9); GLP-1 RAs do, however, present a risk of gastrointestinal adverse events (AEs), leading to frequent discontinuations (10).”
BackgroundSelf-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Basal Insulin Therapy in Type 2 Diabetes
Rosenstock, J., Schwartz, S. L., Clark, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.631 · Cited by 478 · cited 1×
“Basal insulin therapy improves fasting plasma glucose (FPG) and nocturnal hypoglycemia (3), whereas GLP-1 RAs, especially the short-acting compounds, have a significant effect on postprandial plasma glucose (PPG) (4–9).”
BackgroundSelf-citationAmerican Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-er09 · Cited by 379
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288 · cited 1×
“treatment, generally in the 25–30% range (7,9,12).”
Self-citationMeier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Self-citationSeino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Self-citationRiddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Self-citationLingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220 · cited 1×
“combination of insulin degludec and the GLP-1 RA liraglutide (17).”
Background
Research works printed but not linked: 2
- Aroda, 2016, Efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination vs. insulin glargine in patients with T2DM: the LixiLan-L Trial, Diabetes Care, 65, A62
- Sikirica, 2015, Reasons for discontinuation of GLP-1 receptor antagonists: data from a large cross-sectional survey of physicians and type 2 diabetic patients (Abstract), Diabetes Care, 64, A297
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Self-citationGlucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
“Both IDegLira and iGlarLixi have also been studied in patients with type 2 diabetes not adequately controlled on basal insulin.(78,81,83) Treatment intensification with IDegLira versus uptitration of basal insulin was evaluated over 26 weeks in the DUAL program.”
BackgroundMethodResultInfluentialSelf-citationIdentification of barriers to insulin therapy and approaches to overcoming them
Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238
“One important difference is that two co-formulations of iGlarLixi were developed; Pen A, which delivers 10–40 units (U) at a ratio of 2 U IGlar:1 μg lixisenatide in a single injection, and Pen B, which delivers 30–60 U at a ratio of 3 U IGlar:1 μg lixisenatide.(107,108) Both are 492 RUSSELL-JONES ET AL.”
Background2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review
Okemah, J., Peng, J., & Quiñones, M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0819-5 · Cited by 211
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Glycemic variability: how to measure and its clinical implication for type 2 diabetes
Umpierrez, G. E., & P. Kovatchev, B. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.09.010 · Cited by 148
“iGlarLixi, a titratable fixed-ratio combination of insulin glargine plus lixisenatide resulted in greater improvements in overall glycemic control, and thereby, A1C levels, than the components alone in patients with suboptimal glycemic control despite oral and/or basal insulin background therapy (Figure 3).(61,62) In…”
ResultOne hundred years of insulin therapy
Mathieu, C., Martens, P.-J., & Vangoitsenhoven, R. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00542-w · Cited by 164
Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 125
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 150
Huthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care · doi:10.2337/dc20-0498 · Cited by 91
Blonde, L., Rosenstock, J., Del Prato, S., Henry, R., Shehadeh, N., Frias, J., Niemoeller, E., Souhami, E., Ji, C., & Aroda, V. R. (2019) · Diabetes Care · doi:10.2337/dc19-1357 · Cited by 85
“iGlarLixi has been shown to be efficacious and well tolerated in patients with type 2 diabetes uncontrolled by oral antihyperglycemic drugs (OADs) in the LixiLan-O trial (6) or by basal insulin in the LixiLan-L trial (7).”
BackgroundSelf-citationDo GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
Piccoli, G. F., Mesquita, L. A., Stein, C., Aziz, M., Zoldan, M., Degobi, N. A. H., Spiazzi, B. F., Lopes Junior, G. L., Colpani, V., & Gerchman, F. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa891 · Cited by 81
Guja, C., Frías, J. P., Somogyi, A., Jabbour, S., Wang, H., Hardy, E., & Rosenstock, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13266 · Cited by 78
“Furthermore, fixed-ratio combinations of IG plus lixisenatide (iGlarLixi) and insulin degludec plus liraglutide (IDegLira) significantly decrease HbA1c and body weight, compared with their respective basal insulin monocomponents, without increasing hypoglycaemia risk.(24,25) Fixed-ratio combinations may not be suitabl…”
BackgroundSelf-citationInsulin Initiation and Titration in Patients With Type 2 Diabetes
Chun, J. H., Strong, J. L., & Urquhart, S. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0005 · Cited by 92
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Mosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 76
“It is also well tolerated and is associated with a lower rate of gastrointestinal side effects due to the slow titration, compared with GLP-1 RA alone [80].”
BackgroundResultRecent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Yu, J., Lee, S.-H., & Kim, M. K. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.105 · Cited by 65
Jones, K. L., Rigda, R. S., Buttfield, M. D. M., Hatzinikolas, S., Pham, H. T., Marathe, C. S., Wu, T., Lange, K., Trahair, L. G., Rayner, C. K., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13633 · Cited by 66
“Given the marked effect on gastric emptying at this dose, it is uncertain whether a higher dose would slow gastric emptying further, and it is also possible that a lower dose (5 μg) may be clinically effective, which has implications for tolerability and the use of lixisenatide as a fixed-dose combination with insulin…”
BackgroundRosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0393 · Cited by 63
Self-citationImportance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Hershon, K. S., Hirsch, B. R., & Odugbesan, O. (2019) · Clinical Diabetes · doi:10.2337/cd18-0040 · Cited by 67
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Cersosimo, E., Johnson, E. L., Chovanes, C., & Skolnik, N. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13108 · Cited by 52
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
Owens, D. R., Monnier, L., & Barnett, A. H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12977 · Cited by 57
“6%; and 20% and 9% of patients reached the composite endpoint, respectively].(82) Both iGlarLixi and IDegLira mitigate the weight gain seen with insulin, with rates of hypoglycaemia similar to those observed with the basal insulin component of the combination.”
BackgroundResultInfluentialBasal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Meece, J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 51
“LixiLan-L [54] Basal insulin ± B 2 OADs iGlarLixi: - 1.”
BackgroundSeidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Treatment of type 2 diabetes: future approaches
Bailey, C. J., & Day, C. (2018) · British Medical Bulletin · doi:10.1093/brimed/ldy013 · Cited by 61
“A ‘fixed-ratio’ combination of lixisenatide with insulin glargine offers similar efficacy.(31) Future complementary combinations of peptides may be anticipated if additional therapeutic peptides with glucose-lowering and/or weight-lowering properties become available.”
BackgroundOptimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Perreault, L., Rodbard, H. W., Valentine, V., & Johnson, E. L. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0868-9 · Cited by 49
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Valente, T., & Arbex, A. K. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200716201550 · Cited by 53
Moreira, R. O., Cobas, R. A., & Coelho, R. C. L. A. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0327-4 · Cited by 46
“Insulin treat patients The LixiLan-L trial [31] was a 30-week, double-blind trial, designed to confirm the superiority of IGlarLixi in comparison to glargine alone in patients with T2DM inadequately treated with a stable dose of insulin glargine and any other OAD.”
BackgroundTerauchi, Y., Nakama, T., Spranger, R., Amano, A., Inoue, T., & Niemoeller, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14036 · Cited by 42
“Yasuo Terauchi, Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Japan.”
BackgroundMethodInfluentialSelf-citationKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Watada, H., Takami, A., Spranger, R., Amano, A., Hashimoto, Y., & Niemoeller, E. (2020) · Diabetes Care · doi:10.2337/dc19-2452 · Cited by 38
“RAs given concomitantly with long-acting insulins (26,29).”
BackgroundSelf-citationKaneto, H., Takami, A., Spranger, R., Amano, A., Watanabe, D., & Niemoeller, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14005 · Cited by 36
“When a GLP-1 RA is combined with a long-acting insulin, patients experience better overall glycemic control and fewer adverse drug reactions.(7) This is especially true in Asian patients, who tend to have insulin deficiency rather than insulin resistance.”
BackgroundResultInfluentialSelf-citationValentine, V., Goldman, J. D., & Shubrook, J. H. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0287-y · Cited by 37
“IGlarLixi is given by once-daily subcutaneous injection [38, 39], with the injection being administered within 1 h of the first meal of the day [28].”
BackgroundMethodInfluentialFan, M., Jin, C., Li, D., Deng, Y., Lin, Y., Chen, Y., Ma, Y., & Wang, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1289901 · Cited by 37
Shah, N. Z., Abdalla, M. A., Deshmukh, H., & Sathyapalan, T. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211042145 · Cited by 44
Yang, W., Dong, X., Li, Q., Cheng, Z., Yuan, G., Liu, M. R., Xiao, J., Gu, S., Niemoeller, E., Chen, L., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14722 · Cited by 36
Self-citationA review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
Nuffer, W. A., Guesnier, A., & Trujillo, J. M. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817752315 · Cited by 36
Maiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.009 · Cited by 36
Blonde, L., Anderson, J. E., Chava, P., & Dendy, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541790 · Cited by 33
Wysham, C., Bonadonna, R. C., Aroda, V. R., Puig‐Domingo, M., Kapitza, C., Stager, W., Yu, C. H., Niemoeller, E., Souhami, E., Bergenstal, R. M., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12961 · Cited by 31
“5% (69 mmol/mol), despite having been treated for several years with basal insulin and oral drugs.(9) In this trial, treatment with iGlar alone TABLE 1 Continued”
MethodResultSelf-citationCavaiola, T. S., Kiriakov, Y., & Reid, T. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.015 · Cited by 33
Jalleh, R., Pham, H., Marathe, C. S., Wu, T., Buttfield, M. D., Hatzinikolas, S., Malbert, C. H., Rigda, R. S., Lange, K., Trahair, L. G., et al. (2020) · Nutrients · doi:10.3390/nu12071962 · Cited by 29
Yoon, J., Min, S. H., Ahn, C. H., Cho, Y. M., & Hahn, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-22443-1 · Cited by 31
Yuan, X., Guo, X., Zhang, J., Dong, X., Lu, Y., Pang, W., Gu, S., Niemoeller, E., Lin, P., Nian, G., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14803 · Cited by 31
“3%) were similar to those seen in the present study.(7,8) These comparable improvements in glycaemic control were seen alongside differences in final insulin doses [LixiLan-L: 47 U (0.”
ResultSelf-citationDavies, M. J., Leiter, L. A., Guerci, B., Grunberger, G., Ampudia‐Blasco, F. J., Yu, C. H., Stager, W., Niemoeller, E., Souhami, E., & Rosenstock, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12980 · Cited by 29
“In phase III studies, iGlarLixi was administered via two pen injectors, which allowed flexibility for the dose to be titrated according to a patient's insulin requirement (up to 60 U/d) and for Lixi to be administered up to the maximum approved dose (20 μg/d).(2,3) In the LixiLan-O trial, in a population of insulin-na…”
MethodSelf-citationLixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management
McCarty, D., Coleman, M., & Boland, C. L. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017689878 · Cited by 27
“After randomization, doses for both treatment arms, in combination insulin glargine, were increased to target a FPG of less than 100 mg/dL.(30) As expected, there was no significant difference in FPG at the conclusion of the 30-week study; however, there was a 60-mg/dL difference between the lowering of PPG by each ar…”
BackgroundMethodInfluentialEvans, M., Billings, L. K., Håkan‐Bloch, J., Slothuus, U., Abrahamsen, T. J., Andersen, A., & Jansen, J. P. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1409228 · Cited by 30
Peralta, F. G., Al‐Ozairi, E., Jude, E. B., Li, X., & Rosenstock, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14365 · Cited by 29
Self-citationMcCrimmon, R. J., Sifri, S. A., Emral, R., Mohan, V., Sauque‐Reyna, L., Trescolí, C., Lalic, N. M., Alvarez, A., Demil, N., Coudert, M., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14354 · Cited by 31
Self-citationMathieu, C., Giorgino, F., Kim, S. G., Larsen, J. S., Philis‐Tsimikas, A., Ramachandran, A., da Rocha, T. J. C. M., Shankarappa, V. B., Terauchi, Y., & Ji, L. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00096-8 · Cited by 33
Wysham, C. H., Lin, J., & Kuritzky, L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1297669 · Cited by 26
Self-citationGoldenberg, R., & Berard, L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1372118 · Cited by 27
Cai, X., Gao, X., Yang, W., & Ji, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1400011 · Cited by 28
Tabák, Á. G., Anderson, J. E., Aschner, P. J., Liu, M., Saremi, A., Stella, P., Tinahones, F. J., Wysham, C., & Meier, J. J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00735-7 · Cited by 29
Self-citationBillings, L. K., Andreozzi, F., Frederiksen, M., Gourdy, P., Gowda, A., Ji, L., Pletsch‐Borba, L., Suzuki, R., Unnikrishnan, A. G., & Vianna, A. G. D. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00052-x · Cited by 30
Alexopoulos, A.-S., & Buse, J. B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.012 · Cited by 24
“Concurrent initiation of basal insulin and GLP-1 RA can offset weight gain due to insulin, and combination formulations have even demonstrated reductions in weight [20,21].”
BackgroundHinnen, D., & Strong, J. L. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0014 · Cited by 24
Abdi, H., Azizi, F., & Amouzegar, A. (2018) · Intern J Endocrinol Metab · doi:10.5812/ijem.65600 · Cited by 24
“compared GLP-1 agonists alone or as titratable fixed-ratio plus basal insulin with other injectable treatments (92); 26 RCTs (76-84) (86-88, 93-106), lasting 12 to 52 weeks and involving 11,425 patients were in-”
BackgroundGiorgino, F., Caruso, I., & Napoli, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108478 · Cited by 24
Bala, C. G., Cerghizan, A., Mihai, B. M., Moise, M., & Guja, C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060852 · Cited by 26
Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides
Bailey, C. J. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.012 · Cited by 24
“Compared with insulin glargine alone, IGlarLixi produced greater reductions of HbA1c with lower daily amounts of insulin, lower risk of hypoglycaemia and without weight gain in type 2 diabetes patients, similarly to IDegLira [36, 37].”
InfluentialWysham, C., Campos, C., & Kruger, D. F. (2018) · Clinical Diabetes · doi:10.2337/cd17-0064 · Cited by 24
Self-citationRosenstock, J., Handelsman, Y., Vidal, J., Ampudia‐Blasco, F. J., Giorgino, F., Liu, M., Perfetti, R., & Meier, J. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13462 · Cited by 23
“In patients with long-standing uncontrolled T2D, the LixiLan-L trial demonstrated that simultaneous iGlarLixi was associated with significantly greater reductions in HbA1c and body weight compared with iGlar alone.(8) In a similar patient population, the GetGoal Duo-2 study showed that sequential treatment intensifica…”
Self-citationLiakopoulou, P., Liakos, A., Vasilakou, D., Athanasiadou, E. A., Bekiari, E., Kazakos, K., & Τσάπας, Α. (2017) · Endocrine · doi:10.1007/s12020-017-1293-6 · Cited by 25
Polonsky, W. H., Giorgino, F., Rosenstock, J., Whitmire, K., Lew, E., Coudert, M., Alvarez, A., Nicholls, C. J., & McCrimmon, R. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14822 · Cited by 22
Self-citationLiu, M. R., Gu, W., Chen, L., Li, Y., Kuang, H., Du, J., Alvarez, A., Lauand, F., Souhami, E., Zhang, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15724 · Cited by 22
Self-citationTrujillo, J. M., Roberts, M., DEX, T. A., Chao, J., White, J. R., & LaSalle, J. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13444 · Cited by 20
“This was a post hoc analysis of data from two open-label, randomized, parallel-group, multinational, multicentre phase 3 clinical trials.(5,6) LixiLan-L (NCT02058160) compared iGlarLixi (n = 367) with iGlar (n = 369) in patients showing suboptimal glycaemic control on basal insulin 0–2 OADs.”
BackgroundMethodInfluentialAronson, R., Umpierrez, G. E., Stager, W., & Kovatchev, B. P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13580 · Cited by 23
“Patients discontinued the second OAD, optimized their metformin dose over 4 weeks, and were randomized to one of the three treatment groups for 30 weeks.6 The second, LixiLan-L (NCT02058160), compared iGlarLixi with iGlar in 736 patients with T2D inadequately controlled on BI with zero, one or two OADs.7 Any therapy o…”
BackgroundMethodInfluentialPharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update – The User’s Guide
Senior, P. A., Houlden, R. L., Kim, J., MacKay, D., Nagpal, S., Rabi, D. M., Sherifali, D., & BAJAJ, H. S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.002 · Cited by 23
Lisco, G., Tullio, A. D., Disoteo, O., Geronimo, V. D., Piazzolla, G., Pergola, G. D., Giagulli, V. A., Jirillo, E., Guastamacchia, E., Sabbà, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920541 · Cited by 25
“LixiLan-L (48) NCT02058160 (2016) Individually randomized parallelgroup, open-label T2D (>1 year); HbA1c (before randomization) 8.”
Roussel, R., Durán-Garcia, S., Zhang, Y., Shah, S., Darmiento, C., Shankar, R. R., Golm, G. T., Lam, R. L. H., O’Neill, E. A., Gantz, I., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13574 · Cited by 21
Ando, Y., Shigiyama, F., Hirose, T., & Kumashiro, N. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13533 · Cited by 19
Kis, J. T., Nagy, G., & Kovács, G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01128-5 · Cited by 24
“The decrease in HbA1c levels was similar to that in the iGlarLixi arm of the LixiLan-O study (where the participants were previously on OADs only) [6] and greater than that in the iGlarLixi arm of the LixiLan-L study (where the participants were previously on OADs ? basal insulin) [7].”
MethodResultInfluentialHome, P. D., Blonde, L., Kalra, S., Ji, L., Guyot, P., Brulle-Wohlhueter, C., Murray, E. M., Shah, R., Sayre, T., & Shaunik, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14148 · Cited by 22
“In conclusion, this systematic review and NMA present supporting evidence that iGlarLixi, compared with other intensification options such as adding meal-time insulin or switching to premix insulin, is a clinically relevant treatment option for early intensification in individuals with T2D inadequately controlled on b…”
BackgroundInfluentialDyakov, I. N., & Zyryanov, S. K. (2021) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2021-2-4-15 · Cited by 18
Handelsman, Y., Chovanes, C., DEX, T. A., Giorgino, F., SKOLNIK, N., Souhami, E., Stager, W., Niemoeller, E., & Frías, J. P. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.009 · Cited by 24
Self-citationMcCrimmon, R. J., CHENG, A. Y. Y., Galstyan, G. R., Djaballah, K., Li, X., Coudert, M., & Frías, J. P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14844 · Cited by 17
“Other studies have also shown no weight gain when switching from a BI regimen to iGlarLixi.(5,6) Concerns about body weight can be a barrier to intensification of a BI regimen(28) so it is encouraging that iGlarLixi did not result in weight gain.”
BackgroundVedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 19
“In terms of cardiovascular safety, lixisenatide and IGlar did not significantly alter the rate of major cardiovascular events in their respective cardiovascular outcome trials; hazard ratios (lixisenatide:placebo): 1.02 (0.89; 1.17)95% CI, p = 0.81 and (IGlar:standard care): 1.02 (0.94; 1.11)95% CI, p = 0.63 [77,78].”
BackgroundInfluentialOptimizing diabetes treatment in the presence of obesity
Esquivel, M. A., & Lansang, M. C. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84.s1.04 · Cited by 19
Fixed-Dose and Fixed-Ratio Combination Therapies in Type 2 Diabetes
Schlosser, R. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.05.005 · Cited by 22
Frías, J. P., Puig‐Domingo, M., Meneghini, L., Napoli, R., Liu, M., Soltes-Rak, E., & Aroda, V. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13368 · Cited by 15
“demonstrated improved glycaemic control compared with those taking iGlar, without weight gain or increased risk of hypoglycaemia.(2,6)”
BackgroundResultSelf-citationVisolyi, G. Á., Domján, B. A., Svébis, M. M., Péterfi, A., Lovasz, B. D., Mészáros, S., Horváth, V. J., & Tabák, Á. G. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.03.002 · Cited by 18
“For the HbA1c analysis, we only included the LixiLan-L and LixiLan-O trials to be able to reach model consistency.[11, 13] For the fasting glucose analysis, we excluded the EAGLE trial (comparing liraglutide with glargine) as no laboratory measured fasting glucose was reported in the paper.”
BackgroundMethodResultInfluentialGoldman, J. D., & Trujillo, J. M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017717281 · Cited by 18
“The week 30 dose was 47 U /17 μg in the iGlarLixi group and 47 U in the iGlar group.(22) A1C reductions from baseline were significantly greater with iGlarLixi than with iGlar (−1.”
MethodResultInfluentialFrías, J. P., DEX, T. A., Roberts, M., & Kaplan, A. P. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0547-5 · Cited by 18
Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0783-4 · Cited by 16
“5% were also higher in the insulin glargine/lixisenatide group (Table 1; these endpoints were not included in prespecified hierarchical testing procedure) [23].”
BackgroundMethodInfluentialJohnson, E. L., Frías, J. P., & Trujillo, J. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1452515 · Cited by 16
“with iGlarLixi, while having comparable rates of symptomatic hypoglycemia as patients treated with insulin glargine alone [76].”
BackgroundPöhlmann, J., Russel-Szymczyk, M., Holík, P., Rychna, K., & Hunt, B. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0569-7 · Cited by 15
Haluzík, M., Flekač, M., Lengyel, C., Taybani, Z. J., Guja, C., Mihai, B. M., Cerghizan, A., Martinka, E., Kovács, G., & Kempler, P. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00777-2 · Cited by 16
Edelman, S. V., Cassarino, D., Kayne, D. M., DEX, T. A., Li, X., & Pasquel, F. J. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.9.958 · Cited by 22
Falcetta, P., Nicolì, F., Citro, F., Ciccarone, A., Garofolo, M., Prato, S. D., & Bianchi, C. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01974-0 · Cited by 16
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., Bergenstal, R. M., & on behalf of the LixiLan-L Trial Investigators
- Affiliations
- MedStar Health Research Institute (US)
- Dallas Diabetes Research Center (US)
- Rockwood Clinic (US)
- Catalina Research Institute (US)
- Universidade da Coruña (ES)
- Universidad de Guadalajara (MX)
- Sanofi (Japan) (JP)
- Biostatistics, BMD Consulting Inc., Somerset, NJ
- Sanofi (Germany) (DE)
- Sanofi (France) (FR)
- Park Nicollet Health Services (US)
- Corresponding author
- Aroda, Vanita R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-09-20
- Volume
- 39
- Issue
- 11
- Pages
- 1972-1980
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2521422828
- Cited by
- 260
- References
- 16
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 24 · 2023: 23 · 2022: 24 · 2021: 27 · 2020: 28 · 2019: 26 · 2018: 46 · 2017: 28
- FWCI
- 33.47
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-06-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, lixisenatide, basal insulin, type 2 diabetes, glycemic control, HbA1c, metformin, GLP-1 receptor agonists, weight change, hypoglycemia, gastrointestinal adverse effects, inadequate glycemic control
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Insulin Glargine, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Combinations, Drug Evaluation, Preclinical, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Peptides, Body Mass Index, Treatment Outcome, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.